Volume 29, Issue 1 (March 2025)                   Physiol Pharmacol 2025, 29(1): 3-24 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Darabi S, Ariaei A, Charkhat Gorgich E A, Rezaei S, Behruzi M, Abasian Z et al . The pathophysiological signaling and efficacy of medicinal herbal compounds in Alzheimer’s disease. Physiol Pharmacol 2025; 29 (1) : 2
URL: http://ppj.phypha.ir/article-1-2275-en.html
The pathophysiological signaling and efficacy of medicinal herbal compounds in Alzheimer’s disease
Shahram Darabi , Armin Ariaei , Enam Alhagh Charkhat Gorgich , Shohreh Rezaei , Masume Behruzi , Zahra Abasian , Auob Rustamzadeh
Abstract:   (1100 Views)

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a high prevalence worldwide. It is associated with annoying and debilitating cognitive and memory deficits. For many years, various herbs have been consumed to boost memory and other dementia-related complications. Acetylcholinesterase (AChE) inhibitory, antioxidant properties, and neuroprotective effects of medicinal plants have broadened their application in the treatment of neurodegenerative diseases. Among them, compounds of T. grandiflora, including the methanol extract, depicted antioxidant and hydroxy radical scavenging properties. Likewise, Zingiber officinale and resveratrol have been suggested to demonstrate a neuroprotective effect. Besides, there is a long list of herbal medicines with AChE inhibitory action listed as follows: T. grandiflora, A. paniculata, S. officinalis, G. nivalis, A. calamus, N. jatamansi, M. Allemão, C. sativum, C. tubulosa, and silymarin a flavonoid derived from Silybum marianum (L.) Gaertn. Moreover, Ginkgo biloba L., Curcuma longa L, and natural bioactive compounds including silymarin, and resveratrol, can inhibit the formation and progression of amyloid-beta (Aβ), increase synaptic accumulation of acetylcholine, modulate the degree of tau protein phosphorylation, provide oxidative stress protection, and attenuate neuroinflammation. Herbal compounds involved in AD signaling pathways could affect various pathological processes related to AD and may be beneficial for AD treatment. In this review, the impact of medicinal herbs in alleviating AD symptoms is discussed, for which three databases including PubMed, Web of Science, and Scopus were selected with the keywords of Alzheimer’s disease, medical herbs, signaling pathway, and plants

Article number: 2
Keywords: Alzheimer Disease, Antioxidants, Cognition, Oxidative Stress, Herb-Drug Interactions
Full-Text [PDF 756 kb]   (175 Downloads)    
Type of Manuscript: Review | Subject: Neurophysiology/Pharmacology
References
1. Abbas S, Wink M. Epigallocatechin gallate inhibits beta amyloid oligomerization in Caenorhabditis elegans and affects the daf-2/insulin-like signaling pathway. Phytomedicine 2010; 17: 902-909. [DOI:10.1016/j.phymed.2010.03.008]
2. Ahmed F, Chandra J, Urooj A, Rangappa K. In vitro antioxidant and anticholinesterase activity of Acorus calamus and Nardostachys jatamansi rhizomes. Journal of Pharmacy Research 2009; 2: 830-883.
3. Akhtar A, Sah S P. Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer’s disease. Neurochemistry International 2020; 135: 104707. [DOI:10.1016/j.neuint.2020.104707]
4. Alsadat A M, Nikbakht F, Nia H H, Golab F, Khadem Y, Barati M, et al. GSK-3β as a target for apigenin-induced neuroprotection against Aβ 25-35 in a rat model of Alzheimer’s disease. Neuropeptides 2021; 90: 102200. [DOI:10.1016/j.npep.2021.102200]
5. Arbor Ph D S. Targeting amyloid precursor protein shuttling and processing-long before amyloid beta formation. Neural Regeneration Research 2017; 12: 207. [DOI:10.4103/1673-5374.200800]
6. Ariaei A, Ramezani F. The promising impact of Bemcentinib and Repotrectinib on sleep impairment in Alzheimer’s disease. Journal of Biomolecular Structure and Dynamics 2023: 1-17. [DOI:10.1080/07391102.2023.2276876]
7. Arnold S E, Arvanitakis Z, Macauley-Rambach S L, Koenig A M, Wang H-Y, Ahima R S, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nature Reviews Neurology 2018; 14: 168-181. [DOI:10.1038/nrneurol.2017.185]
8. Barage S H, Sonawane K D. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides 2015; 52: 1-18. [DOI:10.1016/j.npep.2015.06.008]
9. Behl T, Kaur I, Sehgal A, Kumar A, Uddin M, Bungau S. The interplay of ABC transporters in Aβ translocation and cholesterol metabolism: implicating their roles in Alzheimer’s disease. Molecular Neurobiology 2021; 58: 1564-1582. [DOI:10.1007/s12035-020-02211-x]
10. Bhat B A, Almilaibary A, Mir R A, Aljarallah B M, Mir W R, Ahmad F, et al. Natural therapeutics in aid of treating alzheimer’s disease: a green gateway toward ending quest for treating neurological disorders. Frontiers In Neuroscience 2022; 16: 884345. [DOI:10.3389/fnins.2022.884345]
11. Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer’s disease. Journal of Alzheimer’s Disease 2009; 18: 413-417. [DOI:10.3233/JAD-2009-1177]
12. Bordoloi S, Pathak K, Devi M, Saikia R, Das J, Kashyap V H, et al. Some promising medicinal plants used in Alzheimer’s disease: an ethnopharmacological perspective. Discover Applied Sciences 2024; 6: 1-20. [DOI:10.1007/s42452-024-05811-7]
13. Borrelli F, Capasso R, Izzo A A. Garlic (Allium sativum L.): adverse effects and drug interactions in humans. Molecular nutrition & Food Research 2007; 51: 1386-1397. [DOI:10.1002/mnfr.200700072]
14. Bosco F, Ruga S, Citraro R, Leo A, Guarnieri L, Maiuolo J, et al. The Effects of andrographis paniculata (Burm. F.) Wall. Ex Nees and andrographolide on neuroinflammation in the treatment of neurodegenerative diseases. Nutrients 2023; 15: 3428. [DOI:10.3390/nu15153428]
15. Buller C L, Loberg R D, Fan M-H, Zhu Q, Park J L, Vesely E, et al. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. American Journal of Physiology-Cell Physiology 2008; 295: 836-843. [DOI:10.1152/ajpcell.00554.2007]
16. Cai Z, Zhao B, Li K, Zhang L, Li C, Quazi S H, et al. Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer’s disease? Journal of Neuroscience Research 2012; 90: 1105-1118. [DOI:10.1002/jnr.23011]
17. Calou I, Bandeira M A, Aguiar-Galvão W, Cerqueira G, Siqueira R, Neves K R, et al. Neuroprotective properties of a standardized extract from Myracrodruon urundeuva Fr. All.(Aroeira-Do-Sertao), as evaluated by a Parkinson’s disease model in rats. Parkinson’s Disease 2014; 2014. [DOI:10.1155/2014/519615]
18. Cambay Z, Baydas G, Tuzcu M, Bal R. Pomegranate (Punica granatum L.) flower improves learning and memory performances impaired by diabetes mellitus in rats. Acta Physiologica Hungarica 2011; 98: 409-420. [DOI:10.1556/APhysiol.98.2011.4.4]
19. Cascella M, Bimonte S, Muzio M R, Schiavone V, Cuomo A. The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: An overview of pre-clinical studies and translational perspectives in clinical practice. Infectious Agents and Cancer 2017; 12: 1-7. [DOI:10.1186/s13027-017-0145-6]
20. Chaudhari K S, Tiwari N R, Tiwari R R, Sharma R S. Neurocognitive effect of nootropic drug Brahmi (Bacopa monnieri) in Alzheimer’s disease. Annals of Neurosciences 2017; 24: 111-122. [DOI:10.1159/000475900]
21. Chen G-f, Xu T-h, Yan Y, Zhou Y-r, Jiang Y, Melcher K, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacologica Sinica 2017; 38: 1205-1235. [DOI:10.1038/aps.2017.28]
22. Chen L M, Xiong Y S, Kong F L, Qu M, Wang Q, Chen X Q, et al. Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activating Akt signaling. Journal of Neurochemistry 2012; 120: 157-164. [DOI:10.1111/j.1471-4159.2011.07275.x]
23. Chen Z-R, Huang J-B, Yang S-L, Hong F-F. Role of cholinergic signaling in Alzheimer’s disease. Molecules 2022; 27: 1816. [DOI:10.3390/molecules27061816]
24. Chesser A S, Ganeshan V, Yang J, Johnson G V. Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons. Nutritional Neuroscience 2016; 19: 21-31. [DOI:10.1179/1476830515Y.0000000038]
25. Cioanca O, Hritcu L, Mihasan M, Hancianu M. Cognitive-enhancing and antioxidant activities of inhaled coriander volatile oil in amyloid β (1-42) rat model of Alzheimer’s disease. Physiology & Behavior 2013; 120: 193-202. [DOI:10.1016/j.physbeh.2013.08.006]
26. Crous-Bou M, Minguillón C, Gramunt N, Molinuevo J L. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimer’s Research & Therapy 2017; 9: 1-9. [DOI:10.1186/s13195-017-0297-z]
27. Dar N J. Neurodegenerative diseases and Withania somnifera (L.): An update. Journal of Ethnopharmacology 2020; 256: 112769. [DOI:10.1016/j.jep.2020.112769]
28. Das R, Rauf A, Akhter S, Islam M N, Emran T B, Mitra S, et al. Role of withaferin a and its derivatives in the management of Alzheimer’s disease: recent trends and future perspectives. Molecules 2021; 26: 3696. [DOI:10.3390/molecules26123696]
29. Das S, Mishra K, Ganju L, Singh S. Andrographolide-A promising therapeutic agent, negatively regulates glial cell derived neurodegeneration of prefrontal cortex, hippocampus and working memory impairment. Journal of Neuroimmunology 2017; 313: 161-175. [DOI:10.1016/j.jneuroim.2017.11.003]
30. Deelchand D K, Shestov A A, Koski D M, Uğurbil K, Henry P G. Acetate transport and utilization in the rat brain. Journal of Nurochemistry 2009; 109: 46-54. [DOI:10.1111/j.1471-4159.2009.05895.x]
31. Devi K P, Shanmuganathan B, Manayi A, Nabavi S F, Nabavi S M. Molecular and therapeutic targets of genistein in Alzheimer’s disease. Molecular Neurobiology 2017; 54: 7028-7041. [DOI:10.1007/s12035-016-0215-6]
32. Ding Q, Shults N V, Gychka S G, Harris B T, Suzuki Y J. Protein expression of angiotensin-converting enzyme 2 (ACE2) is upregulated in brains with Alzheimer’s disease. International Journal of Molecular Sciences 2021; 22: 1687. [DOI:10.3390/ijms22041687]
33. Dohrmann D D, Putnik P, Kovačević D B, Simal-Gandara J, Lorenzo J M, Barba F J. Japanese, Mediterranean and Argentinean diets and their potential roles in neurodegenerative diseases. Food Research International 2019; 120: 464-477. [DOI:10.1016/j.foodres.2018.10.090]
34. Dragicevic N, Smith A, Lin X, Yuan F, Copes N, Delic V, et al. Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer’s amyloid-induced mitochondrial dysfunction. Journal of Alzheimer’s Disease 2011; 26: 507-521. [DOI:10.3233/JAD-2011-101629]
35. Duan S, Guan X, Lin R, Liu X, Yan Y, Lin R, et al. Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer’s disease. Neurobiology of aging 2015; 36: 1792-1807. [DOI:10.1016/j.neurobiolaging.2015.02.002]
36. Dubey T, Chinnathambi S. Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer’s disease. Archives of Biochemistry and Biophysics 2019; 676: 108153. [DOI:10.1016/j.abb.2019.108153]
37. Ebrahimi Shah-abadi M, Ariaei A, Mohammadi H, Shabani A, Rahmani Tanha R, Tavakolian Ferdousie V, et al. Recent advances and future directions in imaging of peripheral nervous system: a comprehensive review for therapeutics approach. Journal of Advances in Medical and Biomedical Research 2023; 31: 415-431. [DOI:10.30699/jambs.31.148.415]
38. Ebrahimpour S, Zakeri M, Esmaeili A. Crosstalk between obesity, diabetes, and alzheimer’s disease: Introducing quercetin as an effective triple herbal medicine. Ageing Research Reviews 2020; 62: 101095. [DOI:10.1016/j.arr.2020.101095]
39. Esfandiari E, Ghanadian M, Rashidi B, Mokhtarian A, Vatankhah A M. The effects of Acorus calamus L. in preventing memory loss, anxiety, and oxidative stress on lipopolysaccharide-induced neuroinflammation rat models. International Journal of Preventive Medicine 2018; 9. [DOI:10.4103/ijpvm.IJPVM_75_18]
40. Frost G, Sleeth M L, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nature Communications 2014; 5: 1-11. [DOI:10.1038/ncomms4611]
41. Geromichalos G D, Lamari F N, Papandreou M A, Trafalis D T, Margarity M, Papageorgiou A, et al. Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies. Journal of Agricultural and Food Chemistry 2012; 60: 6131-6138. [DOI:10.1021/jf300589c]
42. Geun Kim H, Sook Oh M. Herbal medicines for the prevention and treatment of Alzheimer’s disease. Current Pharmaceutical Design 2012; 18: 57-75. [DOI:10.2174/138161212798919002]
43. Gezen-Ak D, Dursun E, Hanağası H, Bilgiç B, Lohman E, Araz Ö S, et al. BDNF, TNFα, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment. Journal of Alzheimer’s Disease 2013; 37: 185-195. [DOI:10.3233/JAD-130497]
44. Ghorbani A, Esmaeilizadeh M. Pharmacological properties of Salvia officinalis and its components. Journal of Traditional and Complementary Medicine 2017; 7: 433-440. [DOI:10.1016/j.jtcme.2016.12.014]
45. Gilad G M, Kagan H M, Gilad V H. Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer’s disease brain. Neuroscience Letters 2005; 376: 210-214. [DOI:10.1016/j.neulet.2004.11.054]
46. Goedert M, Spillantini M G. A century of Alzheimer’s disease. Science 2006; 314: 777-781. [DOI:10.1126/science.1132814]
47. Gomes B A Q, Silva J P B. Neuroprotective mechanisms of resveratrol in Alzheimer’s disease: role of SIRT1. Oxidative Medicine and Cellular Longevity. 2018; 2018: 8152373. [DOI:10.1155/2018/8152373]
48. Govindarajan N, Agis-Balboa R C, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves memory function in an Alzheimer’s disease mouse model when administered at an advanced stage of disease progression. Journal of Alzheimer’s Disease 2011; 26: 187-97. [DOI:10.3233/JAD-2011-110080]
49. Gu L, Lu J, Li Q, Wu N, Zhang L, Li H, et al. A network-based analysis of key pharmacological pathways of Andrographis paniculata acting on Alzheimer’s disease and experimental validation. Journal of Ethnopharmacology 2020; 251: 112488. [DOI:10.1016/j.jep.2019.112488]
50. Guo Q, Zhou Y, Wang C-J, Huang Y-M, Lee Y-T, Su M-H, et al. An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain®) for treating moderate Alzheimer’s disease. American Journal of Alzheimer’s Disease & Other Dementias® 2013; 28: 363-70. [DOI:10.1177/1533317513488907]
51. Gupta V B, Indi S, Rao K. Garlic extract exhibits antiamyloidogenic activity on amyloid-beta fibrillogenesis: relevance to Alzheimer’s disease. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives 2009; 23: 111-5. [DOI:10.1002/ptr.2574]
52. Gómez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nature Reviews Neuroscience 2008; 9: 568-578. [DOI:10.1038/nrn2421]
53. Han Q, Xu N, Chen B, Wu W, Sheng L. Safety and efficacy of Prunella vulgaris preparation in adjuvant treatment of thyroid nodules: A meta-analysis. Medicine 2021; 100: e27490. [DOI:10.1097/MD.0000000000027490]
54. Hanger D P, Byers H L, Wray S, Leung K-Y, Saxton M J, Seereeram A, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. Journal of Biological Chemistry 2007; 282: 23645-54. [DOI:10.1074/jbc.M703269200]
55. Harjotaruno S, Widyawaruyanti A, Sismindari S, Zaini N C. Apoptosis inducing effect of andrographolide on TF-47 human breast cancer cell line. African Journal of Traditional, Complementary and Alternative Medicines 2007; 4: 345-51. [DOI:10.4314/ajtcam.v4i3.31228]
56. Hashiguchi M, Saito T, Hisanaga S-i, Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. Journal of Biological Chemistry 2002; 277: 44525-44530. [DOI:10.1074/jbc.M207426200]
57. He X, Chen X, Yang Y, Liu Y, Xie Y. Acorus calamus var. angustatus Besser: Insight into current research on ethnopharmacological use, phytochemistry, pharmacology, toxicology, and pharmacokinetics. Phytochemistry 2023: 113626. [DOI:10.1016/j.phytochem.2023.113626]
58. Heinrich M, Teoh H L. Galanthamine from snowdrop-the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. Journal of Ethnopharmacology 2004; 92: 147-62. [DOI:10.1016/j.jep.2004.02.012]
59. Hossain M S, Urbi Z, Sule A, Rahman K. Andrographis paniculata (Burm. f.) Wall. ex Nees: a review of ethnobotany, phytochemistry, and pharmacology. The Scientific World Journal 2014; 2014. [DOI:10.1155/2014/274905]
60. Husain M A, Laurent B, Plourde M. APOE and Alzheimer’s disease: From lipid transport to physiopathology and therapeutics. Frontiers in Neuroscience 2021: 85. [DOI:10.3389/fnins.2021.630502]
61. Iqbal K, Liu F, Gong C-X, Alonso A d C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathologica 2009; 118: 53-69. [DOI:10.1007/s00401-009-0486-3]
62. Jatwa V, Khirwadkar P, Dashora K. Indian traditional memory enhancing herbs and their medicinal benefits. Indian Journal of Research in Pharmacy and Biotechnology 2014; 2: 1030.
63. Jiang H-H, Yan F-S, Shen L, Ji H-F. Silymarin versus silibinin: differential antioxidant and neuroprotective effects against H2O2-induced oxidative stress in PC12 cells. Natural Product Communications 2016; 11: 1934578X1601100520. [DOI:10.1177/1934578X1601100520]
64. Jin T, Chi L, Ma C. Agrimonia pilosa: A phytochemical and pharmacological review. Evidence-Based Complementary and Alternative Medicine 2022; 2022. [DOI:10.1155/2022/3742208]
65. John O O, Amarachi I S, Chinazom A P, Adaeze E, Kale M B, Umare M D, et al. Phytotherapy: A promising approach for the treatment of Alzheimer’s disease. Pharmacological Research-Modern Chinese Medicine 2022; 2: 100030. [DOI:10.1016/j.prmcm.2021.100030]
66. Jung M, Park M. Acetylcholinesterase inhibition by flavonoids from Agrimonia pilosa. Molecules 2007; 12: 2130-9. [DOI:10.3390/12092130]
67. Kamran M, Kousar R, Ullah S, Khan S, Umer M F, Rashid H U, et al. Taxonomic distribution of medicinal plants for Alzheimer’s Disease: a cue to novel drugs. International Journal of Alzheimer’s Disease 2020; 2020: 1-15. [DOI:10.1155/2020/7603015]
68. Katoh Y, Iida K, Kang M-I, Kobayashi A, Mizukami M, Tong K I, et al. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Archives of Biochemistry and Biophysics 2005; 433: 342-50. [DOI:10.1016/j.abb.2004.10.012]
69. Khwairakpam A D, Damayenti Y D, Deka A, Monisha J, Roy N K, Padmavathi G, et al. Acorus calamus: a bio-reserve of medicinal values. Journal of Basic and Clinical Physiology and Pharmacology 2018; 29: 107-122. [DOI:10.1515/jbcpp-2016-0132]
70. Kloske C M, Wilcock D M. The important interface between apolipoprotein E and neuroinflammation in Alzheimer’s disease. Frontiers in Immunology 2020; 11: 754. [DOI:10.3389/fimmu.2020.00754]
71. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nature Medicine 2004; 10: 719-726. [DOI:10.1038/nm1058]
72. Kolarova M, García-Sierra F, Bartos A, Ricny J, Ripova D. Structure and pathology of tau protein in Alzheimer disease. International journal of Alzheimer’s Disease 2012; 2012. [DOI:10.1155/2012/731526]
73. Kummer W, Lips K, Pfeil U. The epithelial cholinergic system of the airways. Histochemistry and Cell Biology 2008; 130: 219-234. [DOI:10.1007/s00418-008-0455-2]
74. Kurapati K R V, Atluri V S R, Samikkannu T, Nair M P. Ashwagandha (Withania somnifera) reverses β-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND). PLoS One 2013; 8: e77624. [DOI:10.1371/journal.pone.0077624]
75. Kutluer M, Huang L, Marigo V. Targeting molecular pathways for the treatment of inherited retinal degeneration. Neural Regeneration Research 2020; 15: 1784. [DOI:10.4103/1673-5374.280303]
76. Laribi B, Kouki K, M’Hamdi M, Bettaieb T. Coriander (Coriandrum sativum L.) and its bioactive constituents. Fitoterapia 2015; 103: 9-26. [DOI:10.1016/j.fitote.2015.03.012]
77. Lazarevic-Pasti T, Leskovac A, Momic T, Petrovic S, Vasic V. Modulators of acetylcholinesterase activity: From Alzheimer’s disease to anti-cancer drugs. Current Medicinal Chemistry 2017; 24: 3283-3309. [DOI:10.2174/0929867324666170705123509]
78. Le Page A, Dupuis G, Frost E H, Larbi A, Pawelec G, Witkowski J M, et al. Role of the peripheral innate immune system in the development of Alzheimer’s disease. Experimental Gerontology 2018; 107: 59-66. [DOI:10.1016/j.exger.2017.12.019]
79. Lee C W-C, Lau K-F, Miller C C, Shaw P-C. Glycogen synthase kinase-3β-mediated tau phosphorylation in cultured cell lines. Neuroreport 2003; 14: 257-260. [DOI:10.1097/00001756-200302100-00020]
80. Liu F, Grundke-Iqbal I, Iqbal K, Gong C X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. European Journal of Neuroscience 2005; 22: 1942-1950. [DOI:10.1111/j.1460-9568.2005.04391.x]
81. Machado A C, Souza L P, Saldanha L L, Pieroni L G, Matos A A, Oliveira F A d, et al. “Aroeira”(Myracrodruon urundeuva) methanol extract: the relationship between chemical compounds and cellular effects. Pharmaceutical Biology 2016; 54: 2737-2741. [DOI:10.1080/13880209.2016.1182555]
82. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer’s disease. Neuroscience Research 2006; 54: 197-201. [DOI:10.1016/j.neures.2005.11.009]
83. Malik J, Karan M, Vasisht K. Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi. Pharmaceutical Biology 2011; 49: 1234-1242. [DOI:10.3109/13880209.2011.584539]
84. Mei N, Guo X, Ren Z, Kobayashi D, Wada K, Guo L. Review of Ginkgo biloba-induced toxicity, from experimental studies to human case reports. Journal of Environmental Science and Health, Part C 2017; 35: 1-28. [DOI:10.1080/10590501.2016.1278298]
85. Mietelska-Porowska A, Wojda U. T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer’s disease: potential pools of new biomarkers. Journal of Immunology Research 2017; 2017. [DOI:10.1155/2017/4626540]
86. Mikami M, Takuya O, Yoshino Y, Nakamura S, Ito K, Kojima H, et al. Acorus calamus extract and its component α-asarone attenuate murine hippocampal neuronal cell death induced by l-glutamate and tunicamycin. Bioscience, Biotechnology, and Biochemistry 2021; 85: 493-501. [DOI:10.1093/bbb/zbaa071]
87. Mohammadi H, Ariaei A, Ghobadi Z, Gorgich E A C, Rustamzadeh A. Which neuroimaging and fluid biomarkers method is better in theranostic of Alzheimer’s disease? An umbrella review. IBRO Neuroscience Reports 2024. [DOI:10.1016/j.ibneur.2024.02.007]
88. Mohd Sahardi N F N, Makpol S. Ginger (Zingiber officinale Roscoe) in the prevention of ageing and degenerative diseases: review of current evidence. Evidence-Based Complementary and Alternative Medicine 2019; 2019. [DOI:10.1155/2019/5054395]
89. Moussa C, Hebron M, Huang X, Ahn J, Rissman R A, Aisen P S, et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation 2017; 14: 1. [DOI:10.1186/s12974-016-0779-0]
90. Nagori K, Nakhate K T, Yadav K, Ajazuddin, Pradhan M. Unlocking the Therapeutic Potential of Medicinal Plants for Alzheimer’s Disease: Preclinical to Clinical Trial Insights. Future Pharmacology 2023; 3: 877-907. [DOI:10.3390/futurepharmacol3040053]
91. Naoi M, Inaba-Hasegawa K, Shamoto-Nagai M, Maruyama W. Neurotrophic function of phytochemicals for neuroprotection in aging and neurodegenerative disorders: modulation of intracellular signaling and gene expression. Journal of Neural Transmission 2017; 124: 1515-1527. [DOI:10.1007/s00702-017-1797-5]
92. Okuda M, Hijikuro I, Fujita Y, Teruya T, Kawakami H, Takahashi T, et al. Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors. Bioorganic & Medicinal Chemistry Letters 2016; 26: 5024-8. [DOI:10.1016/j.bmcl.2016.08.092]
93. Paluch Z, Biriczová L, Pallag G, Carvalheiro Marques E, Vargová N, Kmoníčková E. The therapeutic effects of Agrimonia eupatoria L. Physiol Res 2020; 69: 555-71. [DOI:10.33549/physiolres.934641]
94. Panche A N, Chandra S, Diwan A. Multi-target β-protease inhibitors from Andrographis paniculata: in silico and in vitro studies. Plants 2019; 8: 231. [DOI:10.3390/plants8070231]
95. Park Y J, Ko J W, Jeon S, Kwon Y H. Protective Effect of Genistein against Neuronal Degeneration in ApoE(-/-) Mice Fed a High-Fat Diet. Nutrients 2016; 8. [DOI:10.3390/nu8110692]
96. Patil S P, Maki S, Khedkar S A, Rigby A C, Chan C. Withanolide A and asiatic acid modulate multiple targets associated with amyloid-β precursor protein processing and amyloid-β protein clearance. Journal of Natural Products 2010; 73: 1196-1202. [DOI:10.1021/np900633j]
97. Penido A B, De Morais S M, Ribeiro A B, Alves D R, Rodrigues A L M, Dos Santos L H, et al. Medicinal plants from northeastern Brazil against Alzheimer’s disease. Evidence-Based Complementary and Alternative Medicine 2017; 2017. [DOI:10.1155/2017/1753673]
98. Perl D P. Neuropathology of Alzheimer’s disease and related disorders. Neurologic Clinics 2000; 18: 847-864. [DOI:10.1016/S0733-8619(05)70229-2]
99. Porwal O, Ameen M S M, Anwer E T, Uthirapathy S, Ahamad J, Tahsin A. Silybum marianum (Milk Thistle): Review on Its chemistry, morphology, ethno medical uses, phytochemistry and pharmacological activities. Journal of Drug Delivery and Therapeutics 2019; 9: 199-206. [DOI:10.22270/jddt.v9i5.3666]
100. Poulose S M, Carey A N, Shukitt-Hale B. Improving brain signaling in aging: could berries be the answer? Expert Review of Neurotherapeutics 2012; 12: 887-889. [DOI:10.1586/ern.12.86]
101. Qiong W, Jiang N, Wei S, Pei H, Huang H, Zhang Y, et al. Protective Effects and Mechanism of Radix Polygalae Against Neurological Diseases as Well as Effective Substance. Frontiers in Psychiatry 2021: 1837. [DOI:10.3389/fpsyt.2021.688703]
102. Reddy P H, Manczak M, Yin X, Grady M C, Mitchell A, Kandimalla R, et al. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer’s disease. Journal of Investigative Medicine 2016; 64: 1220-1234. [DOI:10.1136/jim-2016-000240]
103. Reddy P H, Manczak M, Yin X, Grady M C, Mitchell A, Tonk S, et al. Protective effects of Indian spice curcumin against amyloid-β in Alzheimer’s disease. Journal of Alzheimer’s Disease 2018; 61: 843-866. [DOI:10.3233/JAD-170512]
104. Rege S D, Geetha T, Griffin G D, Broderick T L, Babu J R. Neuroprotective effects of resveratrol in Alzheimer disease pathology. Frontiers in Aging Neuroscience 2014; 6. [DOI:10.3389/fnagi.2014.00218]
105. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochemical Pharmacology 2014; 88: 640-651. [DOI:10.1016/j.bcp.2013.12.024]
106. Ren K, Jiang T, Zhou H-F, Liang Y, Zhao G-J. Apigenin retards atherogenesis by promoting ABCA1-mediated cholesterol efflux and suppressing inflammation. Cellular Physiology and Biochemistry 2018; 47: 2170-2184. [DOI:10.1159/000491528]
107. Rossi L, Mazzitelli S, Arciello M, Capo C, Rotilio G. Benefits from dietary polyphenols for brain aging and Alzheimer’s disease. Neurochemical Research 2008; 33: 2390-2400. [DOI:10.1007/s11064-008-9696-7]
108. Rustamzadeh A, Sadigh N, Shabani R, Ahadi R, Vahabi Z, Shabani A, et al. Neurochemical Ameliorating of the hippocampus in dyslipidemic Alzheimer patients following silymarin; a double-blind placebo-controlled randomized clinical trial. Medical Journal of the Islamic Republic of Iran 2023; 37. [DOI:10.47176/mjiri.37.123]
109. Saha S, Sadhukhan P, C Sil P. Genistein: a phytoestrogen with multifaceted therapeutic properties. Mini Reviews in Medicinal Chemistry 2014; 14: 920-940. [DOI:10.2174/1389557514666141029233442]
110. Sarker M R, Franks S F. Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies. Geroscience 2018; 40: 73-95. [DOI:10.1007/s11357-018-0017-z]
111. Sato N, Morishita R. The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. Frontiers in aging Neuroscience 2015; 7: 199. [DOI:10.3389/fnagi.2015.00199]
112. Sato S, Cerny R L, Buescher J L, Ikezu T. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. Journal of Neurochemistry 2006; 98: 1573-1584. [DOI:10.1111/j.1471-4159.2006.04059.x]
113. Scassellati C, Galoforo A C, Esposito C, Ciani M, Ricevuti G, Bonvicini C. Promising intervention approaches to potentially resolve neuroinflammation and steroid hormones alterations in Alzheimer’s disease and its neuropsychiatric symptoms. Aging and Disease 2021; 12: 1337. [DOI:10.14336/AD.2021.0122]
114. Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. Journal of Neural Transmission 2006; 113: 1625-1644. [DOI:10.1007/s00702-006-0579-2]
115. Schönthal A H. Adverse effects of concentrated green tea extracts. Molecular Nutrition & Food Research 2011; 55: 874-885. [DOI:10.1002/mnfr.201000644]
116. Sehgal N, Gupta A, Valli R K, Joshi S D, Mills J T, Hamel E, et al. Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proceedings of the National Academy of Sciences 2012; 109: 3510-3505. [DOI:10.1073/pnas.1112209109]
117. Shah-Abadi M E, Ariaei A, Moradi F, Rustamzadeh A, Tanha R R, Sadigh N, et al. In Silico interactions of natural and synthetic compounds with key proteins involved in alzheimer’s disease: prospects for designing new therapeutics compound. Neurotoxicity Research 2023; 41: 408-430. [DOI:10.1007/s12640-023-00648-1]
118. Shaito A, Posadino A M, Younes N, Hasan H, Halabi S, Alhababi D, et al. Potential adverse effects of resveratrol: A literature review. International Journal of Molecular Sciences 2020; 21: 2084. [DOI:10.3390/ijms21062084]
119. Sheeja K, Shihab P, Kuttan G. Antioxidant and anti-inflammatory activities of the plant Andrographis paniculata Nees. Immunopharmacology and Immunotoxicology 2006; 28: 129-140. [DOI:10.1080/08923970600626007]
120. Shen L, Liu L, Li X-Y, Ji H-F. Regulation of gut microbiota in Alzheimer’s disease mice by silibinin and silymarin and their pharmacological implications. Applied Microbiology and Biotechnology 2019; 103: 7141-7149. [DOI:10.1007/s00253-019-09950-5]
121. Shen Y C, Chen C F, Chiou W F. Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism (s) involved in its anti-inflammatory effect. British Journal of Pharmacology 2002; 135: 399-406. [DOI:10.1038/sj.bjp.0704493]
122. Shen Y-C, Chen C-F, Chiou W-F. Suppression of rat neutrophil reactive oxygen species production and adhesion by the diterpenoid lactone andrographolide. Planta Medica 2000; 66: 314-317. [DOI:10.1055/s-2000-8537]
123. Shi C, Liu J, Wu F, Yew D T. Ginkgo biloba extract in Alzheimer’s disease: from action mechanisms to medical practice. International Journal of Molecular Sciences 2010; 11: 107-123. [DOI:10.3390/ijms11010107]
124. Shin J E, Miller B R, Babetto E, Cho Y, Sasaki Y, Qayum S, et al. SCG10 is a JNK target in the axonal degeneration pathway. Proceedings of the National Academy of Sciences 2012; 109: 3696-3705. [DOI:10.1073/pnas.1216204109]
125. Singh A P, Singh R, Verma S S, Rai V, Kaschula C H, Maiti P, et al. Health benefits of resveratrol: Evidence from clinical studies. Medicinal Research Reviews 2019; 39: 1851-1891. [DOI:10.1002/med.21565]
126. Sochocka M, Ochnik M, Sobczyński M, Gębura K, Zambrowicz A, Naporowski P, et al. Ginkgo Biloba Leaf Extract Improves an Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer’s Disease Patients. Nutrients 2022; 14: 2022. [DOI:10.3390/nu14102022]
127. Solfrizzi V, Panza F. Plant-based nutraceutical interventions against cognitive impairment and dementia: meta-analytic evidence of efficacy of a standardized Gingko biloba extract. Journal of Alzheimer’s Disease 2015; 43: 605-611. [DOI:10.3233/JAD-141887]
128. Talebi M, Ilgün S, Ebrahimi V, Talebi M, Farkhondeh T, Ebrahimi H, et al. Zingiber officinale ameliorates Alzheimer’s disease and Cognitive Impairments: Lessons from preclinical studies. Biomedicine & Pharmacotherapy 2021; 133: 111088. [DOI:10.1016/j.biopha.2020.111088]
129. Tandon N, Yadav S S. Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments. Journal of Ethnopharmacology 2020; 255: 112768. [DOI:10.1016/j.jep.2020.112768]
130. Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome. Molecular Neurodegeneration 2017; 12: 1-11. [DOI:10.1186/s13024-017-0206-8]
131. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. International Journal of Nanomedicine 2019; 14: 5541. [DOI:10.2147/IJN.S200490]
132. Tramutola A, Lanzillotta C, Di Domenico F. Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies. Expert Review of Neurotherapeutics 2017; 17: 33-45. [DOI:10.1080/14737175.2017.1244482]
133. Uddin M J, Alam M N, Biswas K, Rahman M A. In vitro antioxidative and cholinesterase inhibitory properties of Thunbergia grandiflora leaf extract. Cogent Food & Agriculture 2016; 2: 1256929. [DOI:10.1080/23311932.2016.1256929]
134. Uddin M J, Russo D, Rahman M M, Uddin S B, Halim M A, Zidorn C, et al. Anticholinesterase activity of eight medicinal plant species: in vitro and in silico studies in the search for therapeutic agents against Alzheimer’s disease. Evidence-Based Complementary and Alternative Medicine 2021; 2021. [DOI:10.1155/2021/9995614]
135. Uddin M, Kabir M. Emerging signal regulating potential of genistein against Alzheimer’s disease: a promising molecule of interest. Frontiers in Cell and Developmental Biology 2019: 197. [DOI:10.3389/fcell.2019.00197]
136. Van Dyck C H, Swanson C J, Aisen P, Bateman R J, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. New England Journal of Medicine 2023; 388: 9-21. [DOI:10.1056/NEJMoa2212948]
137. Viana G, Bandeira M, Matos F. Analgesic and antiinflammatory effects of chalcones isolated from Myracrodruon urundeuva Allemão. Phytomedicine 2003; 10: 189-195. [DOI:10.1078/094471103321659924]
138. Vijayalakshmi S A, Bhat P, Chaturvedi A, Bairy K, Kamath S. Evaluation of the effect of Ferula asafoetida Linn. gum extract on learning and memory in Wistar rats. Indian Journal of Pharmacology 2012; 44: 82. [DOI:10.4103/0253-7613.91873]
139. Vladimir-Knežević S, Blažeković B, Kindl M, Vladić J, Lower-Nedza A D, Brantner A H. Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family. Molecules 2014; 19: 767-782. [DOI:10.3390/molecules19010767]
140. Vogt N M, Kerby R L, Dill-McFarland K A, Harding S J, Merluzzi A P, Johnson S C, et al. Gut microbiome alterations in Alzheimer’s disease. Scientific Reports 2017; 7: 1-11. [DOI:10.1038/s41598-017-13601-y]
141. Walsh M E, Bhattacharya A, Sataranatarajan K, Qaisar R, Sloane L, Rahman M M, et al. The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging. Aging Cell 2015; 14: 957-970. [DOI:10.1111/acel.12387]
142. Wang W, M Bodles-Brakhop A, W Barger S. A role for P-glycoprotein in clearance of Alzheimer amyloid β-peptide from the brain. Current Alzheimer Research 2016; 13: 615-620. [DOI:10.2174/1567205013666160314151012]
143. Wobst H J, Sharma A, Diamond M I, Wanker E E, Bieschke J. The green tea polyphenol (−)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Letters 2015; 589: 77-83. [DOI:10.1016/j.febslet.2014.11.026]
144. Wu C-R, Lin H-C, Su M-H. Reversal by aqueous extracts of Cistanche tubulosa from behavioral deficits in Alzheimer’s disease-like rat model: relevance for amyloid deposition and central neurotransmitter function. BMC Complementary and Alternative Medicine 2014; 14: 1-11. [DOI:10.1186/1472-6882-14-202]
145. Yan S D, Zhu H, Zhu A, Golabek A, Du H, Roher A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nature Medicine 2000; 6: 643-651. [DOI:10.1038/76216]
146. Yang X, Xu S, Qian Y, Xiao Q. Resveratrol regulates microglia M1/M2 polarization via PGC-1α in conditions of neuroinflammatory injury. Brain Behav Immun 2017; 64: 162-172. [DOI:10.1016/j.bbi.2017.03.003]
147. Yiannopoulou K G, Papageorgiou S G. Current and future treatments in Alzheimer disease: an update. Journal of Central Nervous System Disease 2020; 12: 1179573520907397. [DOI:10.1177/1179573520907397]
148. Yoo D Y, Nam Y, Kim W, Yoo K-Y, Park J, Lee C H, et al. Effects of Ginkgo biloba extract on promotion of neurogenesis in the hippocampal dentate gyrus in C57BL/6 mice. Journal of Veterinary Medical Science 2010: 1008230321 [DOI:10.1292/jvms.10-0294]
149. Yu B-C, Chen W-C, Cheng J-T. Antihyperglycemic effect of andrographolide in streptozotocin-induced diabetic rats. Planta Medica 2003; 69: 1075-1079. [DOI:10.1055/s-2003-45185]
150. Zare H, Amiri Ardekani E, Tavakoli A, Bradley R, Tavakoli F, Pasalar M. Reporting of adverse effects of pomegranate in clinical studies: a systematic review. Journal of Complementary and Integrative Medicine 2023; 21: 154-166. [DOI:10.1515/jcim-2022-0247]
151. Zarmouh N O, Messeha S S, Elshami F M, Soliman K F. Natural products screening for the identification of selective monoamine oxidase-B inhibitors. European Journal of Medicinal Plants 2016; 15:14802. [DOI:10.9734/EJMP/2016/26453]
152. Zhang T, Liu N, Cao H, Wei W, Ma L, Li H. Different doses of pharmacological treatments for mild to moderate Alzheimer’s disease: A bayesian network meta-analysis. Frontiers in Pharmacology 2020; 11: 778. [DOI:10.3389/fphar.2020.00778]
153. Zhang W, Feng C, Jiang H. Novel target for treating Alzheimer’s Diseases: Crosstalk between the Nrf2 pathway and autophagy. Ageing Research Reviews 2021; 65: 101207. [DOI:10.1016/j.arr.2020.101207]
154. Zhao H, Li N, Wang Q, Cheng X, Li X, Liu T. Resveratrol decreases the insoluble Aβ1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats. Neuroscience 2015a; 310: 641-649. [DOI:10.1016/j.neuroscience.2015.10.006]
155. Zhao H, Wang Z C, Wang K F, Chen X Y. Aβ peptide secretion is reduced by Radix Polygalae induced autophagy via activation of the AMPK/mTOR pathway. Molecular Medicine Reports 2015b; 12: 2771-2776. [DOI:10.3892/mmr.2015.3781]
156. Zhao X, Cui Y, Wu P, Zhao P, Zhou Q, Zhang Z, et al. Polygalae Radix: A review of its traditional uses, phytochemistry, pharmacology, toxicology, and pharmacokinetics. Fitoterapia 2020; 147: 104759. [DOI:10.1016/j.fitote.2020.104759]
157. Zhou J, Zhang S, Choon-Nam O, Shen H-M. Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. Biochemical pharmacology 2006; 72: 132-144. [DOI:10.1016/j.bcp.2006.04.019]
158. Zuo W, Yan F, Zhang B, Li J, Mei D. Advances in the studies of Ginkgo biloba leaves extract on aging-related diseases. Aging and disease 2017; 8: 812. [DOI:10.14336/AD.2017.0615]
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.